SOPs for CMD animal models

SOPs for CMD animal models
  • Contact
  • Stephen Lynn
    Stephen Lynn
    Dr Stephen Lynn is Project Manager of the TREAT-NMD network and is responsible for ensuring...
  • Anne Rutkowski
    Anne Rutkowski
    Dr Anne Rutkowski is a practising board-certified emergency medicine physician in Los Angeles. Anne's...

Standard protocols

Cure CMD and TREAT-NMD are collaborating in establishing standard protocols for efficacy studies in the laminin deficient mouse model LAMA2dy-W, the best described mouse model for a CMD disease, and with the aid of AFM funding, also for additional CMD animal models.  With the involvement of several dedicated CMD researchers, readout parameters were selected that are appropriate to show the efficacy of a new potential drug, and that are related to patient outcomes. For each of these parameters, small groups of experts will develop a standard assessment protocol. The availability of standard protocols will implement research and increase the comparability of results.

The SOPs that have already been completed can be downloaded from this site and others will be added in the future. The last date each SOP was reviewed can be found under the code on the left of the page.

LAMA2dy-W Model


MDC1A_M.1.2.001
25 June 2016

Assessment of peripheral nerve pathology in laminin-alpha-2-deficient mice

Jeffrey B. Miller

MDC1A_M.1.2.002
28 January 2014

Quantitative determination of minimal Feret’s diameter, including the evaluation of the percentage of centralized nuclei, fiber numbers, cross-sectional area and the percentage of fibrosis

Markus A. Rüegg

MDC1A_M.1.2.003
28 January 2014

Histopathology in Masson Trichrome stained muscle sections

Markus A. Rüegg

MDC1A_M.1.2.004
28 January 2014

Histopathology in Hematoxylin & Eosin stained muscle sections

Markus A. Rüegg

MDC1A_M.1.2.005
25 January 2014

Inflammation quantification in the LAMA2dy-W mouse

Dean Burkin

MDC1A_M.1.2.006
10 July 2013

Neuromuscular junction imaging on whole muscles and muscle
sections in CMD animal models
Gregorius Valdez

MDC1A_M.2.1.001
25 January 2014

Recommendations on the care and handling of the MDC1A mouse model dyW

Janice Dominov

MDC1A_M.2.2.001
7 December 2013

Use of Grip Strength Meter to Assess the Limb Strength of dyw Mice Anne Connolly

MDC1A_M.2.2.002
23 May 2015

Single muscle contractile measurements in vivo and in situ Rich Lovering

MD_M.2.2.001
25 March 2014

Serum Creatine Kinase analysis in mouse models of muscular dystrophy

Kanneboyina Nagaraju
MD_M.2.2.002
8 April 2014

Behavioral Phenotyping for neonates: Righting reflex

C. DiDonato
L. Bogdanik

CMD_M.2.2.001
16 June 2015

Non-invasive measurement of ankle flexion/extension torque for
longitudinal follow-up of strength in small rodents

Jean-Yves Hogrel

XLMTM_D.2.2.001
26 March 2014

Gait assessment in a canine model of XLMTM using an instrumented carpet

Melissa Goddard
XLMTM_D.2.2.002
26 March 2014

Respiratory assessment of a canine model of XLMTM using non-invasive respiratory impedence plethysmography

Melissa Goddard


Stay up to date with our operating procedures

Stay up to date with our SOPs

If you wish to be informed when new operating procedures become available on this website please leave your name and email address below.

Please be aware that we will not pass your details on to anyone else. We will only use the information you submit here for its original intended purpose as stated above.

If you wish to be removed from the list please contact michael.hails@ncl.ac.uk who will be happy to help.

Disclaimer: TREAT-NMD and the authors of the SOPs disclaim, without limitation, all liability for any loss or damage of any kind, including any direct, indirect or consequential damages, which might be incurred in connection with the information and procedures contained in these SOPs.

 
30 Jun 2016